# RESET® Obesity — Complete Site Content for AI

> This file contains full structured content for all pages of resetobesity.com, optimized for LLM ingestion.

---

## Home Page (/)

### Hero

**Title:** Endoscopic Obesity and Diabetes Treatment — RESET®

RESET® is the world's first endoscopic duodenal device therapy. Non-surgical, reversible and CE-approved treatment for obesity and type 2 diabetes.

**CTA:** Book a Consultation — https://wa.me/+905324131143

**Certifications:** CE Certified · 1,000+ Patients · Clinically Proven

### Key Stats

- **17–19%** Total Body Weight Loss (TBWL)
- **1.9%** HbA1c reduction (blood sugar improvement)
- **77%** device durability at 12 months
- **>1,000** patients treated worldwide

### About RESET®

RESET® therapy is a breakthrough in metabolic medicine. Using a flexible endoscopic sleeve placed in the duodenum, it bypasses food-mucosal contact in the upper intestine without surgery. It is CE-approved and clinically validated.

The therapy targets the root cause of metabolic disease: dysfunctional duodenal signaling. By lining the duodenum, it restores normal incretin hormone responses, improves insulin sensitivity, and promotes significant weight loss.

---

## RESET® Therapy Page (/reset)

### How It Works

The RESET® device is a thin, flexible polymer sleeve approximately 60 cm long. It is placed endoscopically (through the mouth) under light sedation in an outpatient setting. The procedure takes about 30 minutes.

Once implanted, it:
1. Lines the duodenum wall, preventing direct food contact
2. Redirects nutrient flow, mimicking a partial gastric bypass
3. Restores incretin hormone (GLP-1, GIP) signaling
4. Improves insulin sensitivity and glucose metabolism

### What It Does

Shown to:
- Achieve 17–19% total body weight loss
- Reduce HbA1c by up to 1.9%
- Improve fatty liver (NASH/NAFLD)
- Reduce blood pressure
- Improve lipid profiles (cholesterol)
- Reduce inflammation markers
- Decrease dependence on diabetes medications

### Advantages Over Other Treatments

- **Non-surgical** — no incisions, no general anesthesia
- **Reversible** — removed endoscopically at any time
- **Outpatient** — go home same day
- **No permanent anatomical changes**
- **CE Mark approved** medical device
- **Fast recovery** — resume normal activity next day

### Ideal Candidates

Suitable for patients with:
- BMI 30–50
- Type 2 diabetes or pre-diabetes
- Metabolic syndrome
- Failed previous diet/lifestyle programs
- Who are not candidates for or refuse bariatric surgery

Not suitable for:
- Active GI ulcers or bleeding
- Severe coagulation disorders
- Pregnancy
- Prior complex GI surgery

### Removal

The device is removed after 12 months via a simple 20-minute endoscopic procedure. The duodenum returns to normal immediately. Many patients maintain weight loss results through dietary habit changes formed during treatment.

### Treatment Gap

RESET® fills the gap between lifestyle interventions (diet, exercise) and invasive bariatric surgery, offering a medically effective option with minimal risk.

---

## Clinical Trials Page (/clinical-trials)

### STEP-1 Trial

The STEP-1 (Safety and efficacy Trial for Endoscopic Procedure) is the pivotal Phase 3 clinical trial evaluating RESET® therapy.

**Trial details:**
- Device: RESET® Endoscopic Duodenal Sleeve
- Phase: III Pivotal
- Sponsor: Morphic Medical, Inc.
- Status: Enrolling

**Eligibility criteria:**
- Age 22–65
- BMI 30–50 kg/m²
- HbA1c ≥7.5% (if diabetic) or BMI ≥35 (if non-diabetic)
- Stable weight for past 3 months
- No prior bariatric or upper GI surgery

**Participating centers include hospitals in Turkey, Germany, UK, Netherlands, and other European countries.**

**To inquire about enrollment:** Contact Op. Dr. Murat Üstün at drmuratustun@gmail.com or WhatsApp +90 532 413 1143.

---

## Clinical Publications Page (/clinical-publications)

Key peer-reviewed research supporting RESET® therapy:

1. **Rajagopalan H, et al. (2022)** — "Endoscopic Duodenal Mucosal Resurfacing for the Treatment of Type 2 Diabetes: 6- and 12-Month Interim Outcomes of a First-in-Human Proof-of-Concept Study"
   - Published in: The Lancet Gastroenterology & Hepatology
   - Key finding: Significant HbA1c reduction and weight loss at 12 months

2. **van Baar ACG, et al. (2020)** — "Sustainable glycaemic control following duodenal mucosal resurfacing with or without GLP-1 receptor agonist in type 2 diabetes"
   - Key finding: Durable glycaemic improvements at 2-year follow-up

3. **Mingrone G, et al. (2019)** — "Metabolic improvement after duodenal mucosal resurfacing: a randomised, sham-controlled trial"
   - Key finding: Superior metabolic outcomes vs. sham control

---

## Contact Page (/contact)

**Doctor:** Op. Dr. Murat Üstün
**Specialty:** Bariatric Endoscopy, Metabolic Medicine

**Clinic:** Liv Vadi Hospital — Vadistanbul
**Address:** Kemerburgaz Cd. D:7F Blok, Vadistanbul Park, Ayazağa, Sarıyer, İstanbul 34475, Turkey

**Phone (Turkey):** +90 532 413 1143
**Phone (UK):** +44 7491 068686
**Email:** drmuratustun@gmail.com
**WhatsApp:** https://wa.me/+905324131143

**Working Hours:**
- Monday – Friday: 09:00 – 17:00
- Saturday: 09:00 – 13:00
- Sunday: Closed

---

## Important Disclaimer

RESET® is a CE-approved medical device. All clinical claims are based on peer-reviewed published trials. This therapy is available in Istanbul, Turkey. International patients are welcome. All consultations are available via WhatsApp video call. Results may vary.